CYTR


Company Update (NASDAQ:CYTR): CytRx Corporation Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

CytRx Corporation (NASDAQ:CYTR) presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas at the …

Company Update (NASDAQ:CYTR): CytRx Corporation Reports 2Q:16 Financial Results

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months endedJune 30, 2016, and …

Stock Update (NASDAQ:CYTR): CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered public offering of an …

Jefferies Slashes Price Target for CytRx Corporation (CYTR) Following Disappointing Phase 3 Trial

Jefferies analyst Chris Howerton weighs in on CytRx Corporation (NASDAQ:CYTR) after the company failed to impress investors with its unsuccessful phase 3 Aldoxorubicin (Aldox) trial in …

FBR Slashes Price Target on CytRx Corporation (CYTR) Following Clinical Trial Setback

Shares of CytRx Corporation (NASDAQ:CYTR) are collapsing, down 66% at time of writing, after the company provided initial results from its Phase III study with aldoxorubicin …

FBR Reiterates Outperform Rating On CytRx Corporation (CYTR) Following Release Of ASCO Abstracts

In a research report released Friday, FBR analyst Christopher James reiterated an Outperform rating on shares of CytRx Corporation (NASDAQ:CYTR), with an $8 price …

Stock Update (NASDAQ:CYTR): CytRx Corporation and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, …

Company Update (NASDAQ:CYTR): CytRx Corporation Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached the target number of progression events …

Biotech Beat: Jefferies Provides Updates on Gilead Sciences, Inc. (GILD) and Cytokinetics, Inc. (CYTK)

Jefferies analysts weighed in on pharma giant Gilead Sciences, Inc. (NASDAQ:GILD) and oncology research firm CytRx Corporation (NASDAQ:CYTR) in light of patent litigation with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts